Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a biopharmaceutical company developing medicines for diseases associated with dysregulated aldosterone. Its lead and only product candidate, lorundrostat, is an oral, selective aldosterone synthase inhibitor designed to reduce aldosterone production. The company is… From the company’s description.
In fiscal 2025, Mineralys Therapeutics, Inc. reported a net loss of $154.65M. Operations used $142.42M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Mineralys Therapeutics, Inc. does
In the company’s own words
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is a biopharmaceutical company developing medicines for diseases associated with dysregulated aldosterone. Its lead and only product candidate, lorundrostat, is an oral, selective aldosterone synthase inhibitor designed to reduce aldosterone production. The company is initially developing it for hypertension, including uncontrolled and resistant hypertension, and is also studying its potential in hypertension with chronic kidney disease and obstructive sleep apnea. Mineralys submitted a U.S. regulatory application for lorundrostat for hypertension in combination with other antihypertensive drugs in December 2025. The company was founded in 2019 and licensed lorundrostat from Tanabe Pharma Corporation in 2020, which discovered the compound and advanced it through early clinical development. Mineralys relies on external manufacturers for clinical-trial materials and has not established a commercial sales or distribution strategy. It reported approximately $1.1 billion in aggregate gross proceeds from securities sales since inception. Its website is https://mineralystx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- RADNOR, PA
- Fiscal year end
- December
- CIK
- 1933414
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Mineralys Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Mineralys Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Mineralys Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Mineralys Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Mineralys Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”